Spark Therapeutics Company Profile (NASDAQ:ONCE)

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

Spark Therapeutics, Inc. (NASDAQ:ONCE) issued its earnings results on Wednesday, August, 2nd. The company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.75) by $0.14. The business earned $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business's revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.04) EPS. View Spark Therapeutics' Earnings History.

17 analysts have issued 12 month price targets for Spark Therapeutics' shares. Their predictions range from $28.00 to $111.00. On average, they expect Spark Therapeutics' share price to reach $91.63 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

Here are some recent quotes from research analysts about Spark Therapeutics stock:

• 1. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
• 2. Cowen and Company analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
• 3. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)
• 4. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
• 5. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Spark Therapeutics saw a decrease in short interest in September. As of September 29th, there was short interest totalling 2,255,175 shares, a decrease of 48.1% from the September 15th total of 4,343,511 shares. Based on an average daily volume of 435,854 shares, the days-to-cover ratio is currently 5.2 days. Approximately 7.1% of the shares of the stock are short sold.

Some companies that are related to Spark Therapeutics include Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN) and NovoCure Limited (NVCR).

Spark Therapeutics' management team includes the folowing people:

• Steven M. Altschuler M.D., Independent Chairman of the Board
• Katherine A. High M.D., President, Chief Scientific Officer, Director
• Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
• Stephen W. Webster, Chief Financial Officer
• John P Furey, Chief Operating Officer
• Federico Mingozzi Ph.D., Chief Scientific Officer
• Joseph W. La Barge Esq., General Counsel
• Daniel R. Faga, Chief Business Officer
• Lars G. Ekman M.D., Ph.D., Independent Director
• Anand Mehra M.D., Independent Director

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Spark Therapeutics stock can currently be purchased for approximately $81.87.